Evidence map›Paper›PMID 41787884›Full record

ArticleJournal of the American Chemical Society2026

Macrocyclic Peptides Containing an Imidazopyridinium (IP

Bo Li, Joshua Parker, Skyler Briggs, Jiajun Dong, Connor Wang, Chung-Wei Fu, James M Burke, Thomas Kodadek

Abstract read
In one paragraph

Article in Journal of the American Chemical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Mitochondria-Targeting Moieties Based on N-Tethered Pyridinium Cations.Angewandte Chemie (International ed. in English) · 2026
    Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Bo LiDepartment of Chemistry, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, 120 Scripps Way, Jupiter, Florida 33458, United States.ORCID 0000-0003-2914-9178
Joshua ParkerDepartment of Chemistry, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, 120 Scripps Way, Jupiter, Florida 33458, United States.
Skyler BriggsDepartment of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, 120 Scripps Way, Jupiter, Florida 33458, United States.
Jiajun DongDepartment of Chemistry, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, 120 Scripps Way, Jupiter, Florida 33458, United States.
Connor WangDepartment of Chemistry, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, 120 Scripps Way, Jupiter, Florida 33458, United States.
Chung-Wei FuDepartment of Chemistry, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, 120 Scripps Way, Jupiter, Florida 33458, United States.ORCID 0000-0003-3113-1073
James M BurkeDepartment of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, 120 Scripps Way, Jupiter, Florida 33458, United States.
Thomas KodadekDepartment of Chemistry, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, 120 Scripps Way, Jupiter, Florida 33458, United States.ORCID 0000-0003-1930-4795

Funding

Development of Ubiquitin-Independent DegradersR01CA290247 · NCI · UNIVERSITY OF FLORIDA · PI Thomas J. Kodadek · 2023 to 2026
$3.3M
Novel platforms for the discovery of bioactive small moleculesR35GM151875 · NIGMS · UNIVERSITY OF FLORIDA · PI Thomas J. Kodadek · 2024 to 2026
$2.0M
NCI NIH HHS R01 CA290247NIGMS NIH HHS R35 GM151875
6 · The paper itself

Abstract

Macrocyclic peptides (MPs) have emerged as interesting therapeutic candidates due to their ability to engage difficult protein targets with high affinity and selectivity. However, their application to intracellular targets is limited by the poor passive membrane permeability of most MPs. We previously showed that incorporation of an imidazopyridinium (IP

Indexed as

Cell Membrane PermeabilityImidazolesMacrocyclic CompoundsPeptides, CyclicPyridinium CompoundsHumansImidazolesMacrocyclic CompoundsPeptides, CyclicPyridinium Compounds

Identifiers

PMID41787884
PMCPMC13242635

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.